MY205948A - Anti-alpha-synuclein antibodies - Google Patents
Anti-alpha-synuclein antibodiesInfo
- Publication number
- MY205948A MY205948A MYPI2020002453A MYPI2020002453A MY205948A MY 205948 A MY205948 A MY 205948A MY PI2020002453 A MYPI2020002453 A MY PI2020002453A MY PI2020002453 A MYPI2020002453 A MY PI2020002453A MY 205948 A MY205948 A MY 205948A
- Authority
- MY
- Malaysia
- Prior art keywords
- alpha
- alpha synuclein
- antibodies
- synuclein antibodies
- fibrils
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720975.0A GB201720975D0 (en) | 2017-12-15 | 2017-12-15 | Anti-alpha synuclein antibodies |
| PCT/EP2018/084697 WO2019115674A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY205948A true MY205948A (en) | 2024-11-21 |
Family
ID=61009086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2020002453A MY205948A (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11261242B2 (enExample) |
| EP (1) | EP3724224A1 (enExample) |
| JP (2) | JP7292279B2 (enExample) |
| KR (1) | KR102789446B1 (enExample) |
| CN (1) | CN111479826B (enExample) |
| AR (1) | AR115192A1 (enExample) |
| AU (1) | AU2018382530B2 (enExample) |
| BR (1) | BR112020010504A2 (enExample) |
| CA (1) | CA3083199A1 (enExample) |
| CL (1) | CL2020001605A1 (enExample) |
| EA (1) | EA202091478A1 (enExample) |
| EC (1) | ECSP20039623A (enExample) |
| GB (1) | GB201720975D0 (enExample) |
| IL (1) | IL275187A (enExample) |
| MA (1) | MA51135A (enExample) |
| MX (2) | MX2020005691A (enExample) |
| MY (1) | MY205948A (enExample) |
| PE (1) | PE20201061A1 (enExample) |
| PH (1) | PH12020551007A1 (enExample) |
| SG (1) | SG11202004502SA (enExample) |
| TN (2) | TN2021000169A1 (enExample) |
| TW (2) | TW202332692A (enExample) |
| UA (1) | UA126295C2 (enExample) |
| UY (1) | UY38010A (enExample) |
| WO (1) | WO2019115674A1 (enExample) |
| ZA (2) | ZA202003542B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11142570B2 (en) | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| WO2020079113A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| CA3150726A1 (en) * | 2019-09-20 | 2021-03-25 | Jing Guo | Anti-alpha-synuclein antibodies and methods of use thereof |
| US20230025256A1 (en) * | 2019-12-04 | 2023-01-26 | Simon Friedman | Protein blocking assembly and methods of making and using |
| KR20240176098A (ko) * | 2023-06-14 | 2024-12-24 | 경상국립대학교산학협력단 | 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU2002221132A1 (en) | 2000-12-13 | 2002-07-01 | Taisho Pharmaceutical Co. Ltd. | Novel antibody |
| EP1572894B1 (en) | 2001-11-21 | 2016-04-13 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| HUE035044T2 (en) | 2003-05-19 | 2018-05-02 | Prothena Biosciences Ltd | Truncated fragments of alpha-synuclein in Lewy-body disease |
| US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
| WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| PL2583978T3 (pl) | 2007-02-23 | 2016-07-29 | Prothena Biosciences Ltd Co | Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| LT3067066T (lt) * | 2007-02-23 | 2019-06-25 | Prothena Biosciences Limited | Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas |
| LT2282758T (lt) | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams |
| PT2370466E (pt) | 2008-12-19 | 2015-09-21 | Univ Zuerich | Autoanticorpos humanos anti-alfa-sinucleína |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| RU2555526C2 (ru) * | 2010-02-26 | 2015-07-10 | Байоарктик Ньюросайенс Аб | Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| EP2635906A4 (en) | 2010-11-05 | 2014-04-02 | Univ Brandeis | Ice inhibiting compounds and uses thereof |
| DE102011008153B4 (de) | 2011-01-08 | 2018-08-09 | Aj Roboscreen Gmbh | Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein |
| AU2012272790B2 (en) * | 2011-06-23 | 2016-10-06 | Biogen International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
| EP3378535B1 (en) * | 2011-10-28 | 2023-01-04 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| KR102086061B1 (ko) | 2012-01-27 | 2020-03-11 | 프로테나 바이오사이언시즈 리미티드 | 알파-시누클레인을 인식하는 인간화된 항체 |
| ES2856272T3 (es) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
| UA118441C2 (uk) * | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| WO2015051159A1 (en) | 2013-10-02 | 2015-04-09 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| EP3071974A2 (en) | 2013-11-19 | 2016-09-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
| PL3071597T3 (pl) | 2013-11-21 | 2020-11-30 | F.Hoffmann-La Roche Ag | Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania |
| WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US10155030B2 (en) | 2014-05-23 | 2018-12-18 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| JP6980953B2 (ja) | 2014-09-11 | 2021-12-15 | ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ミスフォールディングタンパク質の検出 |
| WO2016040905A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded alpha synuclein protein |
| WO2016040903A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded amyloid beta protein |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| CA2994518C (en) | 2015-08-25 | 2025-05-06 | Prothena Biosciences Limited | METHODS FOR DETECTING PHOSPHORYLATED ALPHA-SYNUCLEIN |
| AU2016361350B2 (en) | 2015-11-23 | 2023-04-06 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
| US10766954B2 (en) | 2016-04-06 | 2020-09-08 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
| EA038358B1 (ru) | 2016-06-02 | 2021-08-13 | Медиммун Лимитед | Антитела к альфа-синуклеину и их применение |
| GB201611840D0 (en) | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| US20190194324A1 (en) | 2016-08-23 | 2019-06-27 | The Johns Hopkins University | THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR |
| JP7217229B2 (ja) | 2016-11-15 | 2023-02-02 | ハー・ルンドベック・アクチエゼルスカベット | シヌクレイノパチーの治療のための薬剤、使用および方法 |
| US20180134776A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (4H6) |
| US20180134777A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (11D12) |
| US20180134775A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (7A11) |
| US20190315846A1 (en) | 2016-12-12 | 2019-10-17 | The Michael J. Fox Foundation For Parkinson's Research | Antibodies to Human Alpha-Synuclein |
| ES3008133T3 (en) | 2016-12-16 | 2025-03-21 | H Lundbeck As | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| AU2018206279B2 (en) | 2017-01-06 | 2020-09-03 | Abl Bio Inc. | Anti-alpha-syn antibody and use thereof |
| ES2970504T3 (es) | 2017-01-09 | 2024-05-29 | California Inst Of Techn | Uso de la microbiota intestinal en el diagnóstico de la enfermedad de Parkinson |
| US11142570B2 (en) * | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| JOP20190227A1 (ar) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
| CN110869763B (zh) | 2017-05-16 | 2022-07-29 | 安培里翁公司 | 错误折叠tau蛋白质的检测 |
| WO2018237338A1 (en) | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
-
2017
- 2017-12-15 GB GBGB1720975.0A patent/GB201720975D0/en not_active Ceased
-
2018
- 2018-12-13 AU AU2018382530A patent/AU2018382530B2/en active Active
- 2018-12-13 JP JP2020532596A patent/JP7292279B2/ja active Active
- 2018-12-13 SG SG11202004502SA patent/SG11202004502SA/en unknown
- 2018-12-13 WO PCT/EP2018/084697 patent/WO2019115674A1/en not_active Ceased
- 2018-12-13 EA EA202091478A patent/EA202091478A1/ru unknown
- 2018-12-13 US US16/771,993 patent/US11261242B2/en active Active
- 2018-12-13 UA UAA202002941A patent/UA126295C2/uk unknown
- 2018-12-13 KR KR1020207019487A patent/KR102789446B1/ko active Active
- 2018-12-13 MX MX2020005691A patent/MX2020005691A/es unknown
- 2018-12-13 CN CN201880080854.1A patent/CN111479826B/zh active Active
- 2018-12-13 TN TNP/2021/000169A patent/TN2021000169A1/en unknown
- 2018-12-13 EP EP18829767.5A patent/EP3724224A1/en active Pending
- 2018-12-13 TN TNP/2020/000069A patent/TN2020000069A1/en unknown
- 2018-12-13 MY MYPI2020002453A patent/MY205948A/en unknown
- 2018-12-13 BR BR112020010504-0A patent/BR112020010504A2/pt unknown
- 2018-12-13 PE PE2020000707A patent/PE20201061A1/es unknown
- 2018-12-13 CA CA3083199A patent/CA3083199A1/en active Pending
- 2018-12-13 MA MA051135A patent/MA51135A/fr unknown
- 2018-12-14 AR ARP180103657A patent/AR115192A1/es unknown
- 2018-12-14 UY UY0001038010A patent/UY38010A/es not_active Application Discontinuation
- 2018-12-14 TW TW112114559A patent/TW202332692A/zh unknown
- 2018-12-14 TW TW107145283A patent/TWI801469B/zh active
-
2020
- 2020-06-07 IL IL275187A patent/IL275187A/en unknown
- 2020-06-12 ZA ZA2020/03542A patent/ZA202003542B/en unknown
- 2020-06-14 PH PH12020551007A patent/PH12020551007A1/en unknown
- 2020-06-15 CL CL2020001605A patent/CL2020001605A1/es unknown
- 2020-07-13 MX MX2024013356A patent/MX2024013356A/es unknown
- 2020-07-14 EC ECSENADI202039623A patent/ECSP20039623A/es unknown
-
2021
- 2021-05-21 ZA ZA2021/03456A patent/ZA202103456B/en unknown
-
2022
- 2022-01-26 US US17/585,174 patent/US20220220192A1/en active Pending
-
2023
- 2023-06-05 JP JP2023092397A patent/JP7627300B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551006A1 (en) | Anti-alpha synuclein antibodies | |
| PH12020551007A1 (en) | Anti-alpha-synuclein antibodies | |
| PH12019502793A1 (en) | Aadc polynucleotides for the treatment of parkinson`s disease | |
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| ZA201801083B (en) | Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof | |
| MD4733B1 (ro) | Anticorpi anti-TIGIT | |
| MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
| MX2017005834A (es) | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. | |
| MX2019009117A (es) | Anticuerpos anti alfa-sinucleina y usos de los mismos. | |
| PH12017500032A1 (en) | Improved a� protofibril binding antibodies | |
| MX2015015249A (es) | Peptidos terapeuticos. | |
| WO2016044189A8 (en) | Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists | |
| MY167232A (en) | Polypeptides binding to human complement c5 | |
| WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| UA117933C2 (uk) | Поліпептид, здатний зв'язувати с5-компонент комплементу людини | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MX2016008968A (es) | Compuestos organicos. |